Exosomes are the phospholipid-membrane-bound subpopulation of extracellular vesicles
derived from the plasma membrane. The main activity of exosomes is cellular …

Simple Summary Cutaneous melanoma represents the most aggressive form of skin cancer
and its occurrence, development, and progression are based on the accumulation of several …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Background The outcome of patients with macroscopic stage III melanoma is poor.
Neoadjuvant treatment with ipilimumab plus nivolumab at the standard dosing schedule …

The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …

Abstract Treatment with therapy targeting BRAF and MEK (BRAF/MEK) has revolutionized
care in melanoma and other cancers; however, therapeutic resistance is common and …

Tumor‐agnostic therapies represent a paradigm shift in oncology by altering the traditional
means of characterizing tumors based on their origin or location. Instead, they zero in on …

Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional
oncolytic immunotherapy approved for the treatment of unresectable melanoma. The …

The recent US Food and Drug Administration (FDA) approval of the dabrafenib/trametinib
combination as a tissue-agnostic treatment for solid tumors with BRAF V600E mutation is the …

Immune checkpoint inhibitors and BRAF-targeted therapy each improve survival in
melanoma. Immune changes early during targeted therapy suggest the mechanisms of each …